Friday - May 16, 2025
LAS VEGAS and RENO, Nev., Oct. 2, 2024 /PRNewswire/ -- Ambetter from SilverSummit Healthplan, a product offered by a Centene Corporation (NYSE: CNC) company. which provides insurance to under-insured and uninsured populations through the State Based Exchange, will offer a variety of affordable health insurance plans in Nevada for plan year 2025. Open enrollment for the Health Insurance Marketplace® for Nevada runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Nevadans can count on Ambetter from SilverSummit Healthplan. As the only health plan offered in all 17 Nevada counties since 2017, Ambetter's large provider network offers access to primary care and specialists to support your healthcare needs, wherever you may live in our great state," said SilverSummit Healthplan President and Chief Executive Officer Eric Schmacker.
Ambetter from SilverSummit Healthplan offers its members access to quality care, convenient services and valuable rewards. 2025 benefits and offerings include:
Nevada residents interested in learning more about Ambetter from SilverSummit Healthplan or enrolling in a health plan during the open enrollment period may visit Ambetter.SilverSummitHealthplan.com.
About Ambetter from SilverSummit Healthplan
Ambetter from SilverSummit Healthplan serves under-insured and uninsured populations through the Nevada State Based Exchange, Nevada Health Link. Ambetter from SilverSummit Healthplan is underwritten by SilverSummit Healthplan, Inc., which is a Qualified Health Plan issuer in Nevada. For more information, visit ambetterhealth.com/en/nv. This is a solicitation for insurance. For information on your right to receive an Ambetter from SilverSummit Healthplan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$60.06 |
Daily Change: | 0.59 0.99 |
Daily Volume: | 6,546,624 |
Market Cap: | US$30.320B |
April 25, 2025 February 24, 2025 February 04, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load